Program
alisertib
Also written as “Alisertib”, “[^14C]-alisertib” and “Alisertib (MLN8237)”.
Its studies are mostly in Lymphoma · Small Cell Lung Carcinoma · Breast Neoplasms · Ovarian Neoplasms · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.
Drug pageMLN 8237: every studyAll 59 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 200 open or running | phase 3since Nov 28, 2011 | Jul 12, 2007 | none ahead |
| Puma Biotechnology | 33 open or running | phase 2since Sep 27, 2023 | Sep 27, 2023 | Oct 30, 2027phase 2 · NCT06095505 |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Jul 6, 2014 | Jul 6, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Puma Biotechnology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 27, 2023First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT06095505 · 120 planned · United States
- Apr 12, 2024Phase 2 study in Breast NeoplasmsNCT06369285 · 225 planned · United States, Portugal, Spain
- Mar 6, 2026Phase 2 study in Small Cell Lung CarcinomaNCT07465757 · 50 planned · United States, France, Poland and more
Ahead
- Oct 30, 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT06095505
- Dec 30, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06369285
- Mar 31, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07465757
TargetBeta
“Serine/threonine-protein kinase Aurora-A inhibitor”ChEMBL 37, by rule
Studies
All 3 Puma Biotechnology leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07465757Small Cell Lung Carcinoma · United States, France, Poland and more | 2 | Recruiting | Mar 31, 2028 | 50 |
| NCT06369285Breast Neoplasms · United States, Portugal, Spain | 2 | Recruiting | Dec 30, 2027 | 225 |
| NCT06095505Small Cell Lung Carcinoma · United States | 2 | Recruiting | Oct 30, 2027 | 120 |
How it is read
Names in the registry
- “Alisertib”, 23 entries
- “alisertib”, 2 entries
- “[^14C]-alisertib”, 1 entry
- “Alisertib (MLN8237)”, 1 entry
- “MLN8237 (Alisertib)”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, 6 studies
- Small Cell Lung Carcinoma, 3 studies
- Breast Neoplasms, 2 studies
- Ovarian Neoplasms, 2 studies
- Lymphoma, Large B-Cell, Diffuse, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.